Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 208

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 208
---
 The partner would have a data stream that drives their adoption and
business model, while Profusa would benefit from accessing a large user population without the associated marketing and user acquisition
costs.

Key Opinion Leaders (KOLs)

Profusa has worked with a small
number of key opinion leaders (KOLs) in both oxygen and glucose applications, receiving their advice and expertise on product development,
physician use cases, clinical needs, and clinical study support. In certain instances, KOLs are the principal investigators in Profusa’s
clinical studies and have summarized its product and clinical data in podium talks at major conferences and through publications. With
the exception of two KOLs who provided services to Profusa and received stock options for 10,000 shares and 30,000 shares, respectively,
of Profusa’s common stock, KOLs are not compensated or provided equity awards; however, KOLs do receive customary expense reimbursement.

<div align='center'>119</div>

Intellectual Property

Profusa protects its intellectual
property through patents, trade secrets, and copyright/trademarks. Additionally, Profusa requires all officers, employees, and third parties
to enter into standard agreements containing provisions requiring confidentiality of proprietary information and assignment to Profusa
of all inventions made during the course of their employment or consulting relationship. Profusa also enter into nondisclosure agreements
with its commercial counterparties and limits access to, and distribution of, its proprietary information. Except in the case of certain
software, Profusa currently require no 3 party licenses.

Patents and applications cover
several different technology classes, including in vivo sensors, sensor signaling chemistry compositions and scaffolding compositions,
methods of and apparatus for sensor interrogation by fluorescent readers, data reduction algorithms for signal processing, and combined
biochemical data and sensor data methods. As of July 23, 2023, Profusa owns 20 issued U.S. patents; 80 rest-of-world patents,
including patents in Australia, Belgium, Canada, China, Europe, France, Germany, Hong Kong, India, Italy, Ireland, Japan, the Netherlands,
South Korea, and the United Kingdom; 14 pending U.S. patents; and 63 pending rest-of-world patents, including pending patents in
Australia, Canada, China, Europe, Germany, Hong Kong, India, Israel, Japan and South Korea. Profusa’s issued patents expire
between March 2030 and January 2040.

The table below summarizes
Profusa’s portfolio of issued